Model ApoE - Genetic Testing

The PrecivityAD® test measures the concentrations of amyloid beta 42 and 40 (Aβ42 and Aβ40), as well as the presence of Apolipoprotein E (ApoE) isoforms in the blood. The test indicates if an individual is likely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. ApoE4 genotype is a significant risk factor for brain amyloid accumulation and Alzheimer’s disease, and its incorporation into C2N’s proprietary algorithm increases the accuracy of the test. Using data from 686 patients, an algorithm based on plasma Aβ42/40 ratio, ApoE genotype, and patient age improved the separation between amyloid PET positive versus amyloid PET negative patients, as compared to using the Aβ42/40 ratio alone. For additional information about ApoE and sharing the results of ApoE genotype testing with your patients as part of the PrecivityAD® blood test, please download the ApoE overview.